908 Devices Inc. develops and sells measurement devices for chemical and biochemical analysis in North America, Europe, the Middle East, Africa, and the Asia Pacific. It offers handheld and desktop mass spectrometry (Mass Spec) devices for the point-of-need applications in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. Its products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and ZipChip, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. 908 Devices Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
IPO Year: 2020
Exchange: NASDAQ
Website: 908devices.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
11/13/2024 | $12.00 → $4.00 | Outperform → Market Perform | Leerink Partners |
2/7/2023 | $14.00 | Overweight | Stephens |
3/8/2022 | $40.00 → $30.00 | Outperform | SVB Leerink |
10/15/2021 | Outperform | Cowen |
8-K - 908 Devices Inc. (0001555279) (Filer)
8-K - 908 Devices Inc. (0001555279) (Filer)
144 - 908 Devices Inc. (0001555279) (Subject)
SD - 908 Devices Inc. (0001555279) (Filer)
SCHEDULE 13G/A - 908 Devices Inc. (0001555279) (Subject)
10-Q - 908 Devices Inc. (0001555279) (Filer)
8-K - 908 Devices Inc. (0001555279) (Filer)
DEFA14A - 908 Devices Inc. (0001555279) (Filer)
DEF 14A - 908 Devices Inc. (0001555279) (Filer)
SCHEDULE 13G - 908 Devices Inc. (0001555279) (Subject)
908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, Analytics R&D at Repligen Corporation (NASDAQ:RGEN), and a 908 Devices Co-founder, to serve on its Board of Directors, effective immediately. Dr. Brown co-founded 908 Devices and served as the company's Chief Technology Officer & Vice President of Research & Development from February 2012 to March 2023, and as its Chief Product Officer from March 2023 until March 2025 when Repligen purchased the company's bioprocessing portfolio. Prior to 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ:AAPL) lead
908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that the Metropolitan Washington Council of Governments (COG) has purchased eight XplorIR devices, one for each of the seven counties and District of Columbia, which comprise the COG. The devices were shipped in Q1 2025, with training taking place in Q2 2025. The handheld XplorIR device accurately detects, identifies, and quantifies 5,000 unknown gas and vapor chemical threats in seconds. The device has simple controls, an intuitive display and is built for harsh environments, making it easy for first responders to use in emergency situations. "The XplorIR is a crucial addition t
The handheld mass spectrometers are now in active use for trace detection and identification of drugs and explosives for customs and border patrol applications 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announced that the Romanian Customs Authority has fully deployed 27 MX908 devices across its border operations. The units were delivered earlier this year and are now actively supporting frontline officers with real-time identification of trace chemicals, enhancing the country's ability to monitor cross-border movement and investigate suspicious substances with speed and precision. "We have already experienced the benefits of the MX
908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will participate in the upcoming William Blair 45th Annual Growth Stock Conference. 908 Devices' management is scheduled to present on Wednesday, June 4 at 4 p.m. Central Time / 5 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: www.908devices.com. About 908 Devices 908 Devices is revolutionizing chemical analysis with its simple handheld devices, addressing life-altering applications. The Company's d
Revenue from continuing operations grew 59% compared to prior year, driven by an increase in product and service revenue 908 Devices Inc. (NASDAQ:MASS) a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended March 31, 2025. "We are off to a strong start in 2025, with first-quarter revenue exceeding our expectations and the transformation to 908 Devices 2.0 already delivering both top-line growth and meaningful cost reductions," said Kevin J. Knopp, CEO and Co-founder. "With a sharpened focus, a strengthened financial position, and macro trends in
The company's handheld devices are incorporated in strategic CBRN stockpiles 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announced that its devices for rapid chemical detection at the point of need are being included in strategic stockpiles within Europe as part of rescEU, an EU-funded project that is establishing a reserve of disaster response capabilities. These reserves include stockpiles of chemical, biological, radiation and nuclear (CBRN) capabilities for detection, sampling, identification and monitoring due to unintentional disasters or intentional attacks. Over the past six months, the Company has shipped 108 devices to Europ
Multiple handheld MX908 devices will be deployed to detect, identify and mitigate illicit drugs like fentanyl, protecting communities amid the opioid crisis 908 Devices Inc. (NASDAQ:MASS), a pioneer in purpose-built handheld devices for chemical analysis, announces a $2M order from the Texas Department of Public Safety for its MX908 handheld mass spectrometry device. This investment in advanced tools for drug detection builds on an initial order placed last year for several MX908 devices, and is funded through the Community Oriented Policing Services (COPS) grant, a federally funded, state-administered program. The MX908 provides first responders with fast, actionable information when dea
At least 55% reported revenue growth from continuing operations compared to prior year 908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for safety and defense tech applications, today announced preliminary unaudited financial results for the quarter ended March 31, 2025. Preliminary unaudited revenue from continuing operations for the first quarter of 2025 is expected to be at least $11.5 million, compared to $7.4 million of revenue from continuing operations in the first quarter of 2024, reflecting reported growth of approximately 55%. First quarter revenues do not include approximately $1.1 million of additional re
908 Devices Inc. (NASDAQ:MASS), a pioneer in purpose-built handheld devices for chemical analysis, announces that it has received a $1.7 million order from the Ministry of Health of Ukraine for its MX908 handheld mass spectrometry device with Aero module for priority shipment in the first quarter 2025. The devices will be part of an environmental testing kit in a post-war environment and will be used primarily to detect and identify trace substances of hazardous materials, including explosives. The MX908 handheld device utilizes the company's proprietary High Pressure Mass Spectrometry (HPMS) technology to detect and identify hazardous substances including chemical agents, explosives, and
Divested desktop portfolio to Repligen for $70 million, including the MAVEN, MAVERICK, REBEL and ZipChip products Fourth quarter 2024 revenue increases 31% and full year 2024 revenue increases 19% compared to prior year Initiates revenue outlook for 2025 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today reported financial results for the quarter and full year ended December 31, 2024. Strategic Transformation Realized 908 Devices cements its unique position as a market-leading provider of analytical tools for tackling critical public health and safety crises through the divestiture of its bioprocessing desktop assets to